ECSP003616A - MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA - Google Patents
MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFAInfo
- Publication number
- ECSP003616A ECSP003616A ECSP003616A ECSP003616A EC SP003616 A ECSP003616 A EC SP003616A EC SP003616 A ECSP003616 A EC SP003616A EC SP003616 A ECSP003616 A EC SP003616A
- Authority
- EC
- Ecuador
- Prior art keywords
- ifn
- peg
- association
- alfa
- alpha
- Prior art date
Links
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 title 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El empleo de una cantidad terapéuticamente efectiva de IFN-alfa o PEG-IFN -alfa en asociación con una cantidad terapéuticamente efectiva de una sal farmacéuticamente aceptable o profármaco de ácido micofenólico para la preparación de medicamentos para tratar pacientes con enfermedades hepáticas. Loas componentes que administran durante un periodo de tiempo por lo menos suficiente para reducir la cantidad de HCV-RNA presente en la sangre periférica de dicho paciente a menos de 100 copias/ml a 24 semanas después de terminar el tratamiento.The use of a therapeutically effective amount of IFN-alpha or PEG-IFN-alpha in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the preparation of medicaments for treating patients with liver diseases. The components administered for a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies / ml at 24 weeks after the end of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003616 ECSP003616A (en) | 2000-08-11 | 2000-08-11 | MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003616 ECSP003616A (en) | 2000-08-11 | 2000-08-11 | MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003616A true ECSP003616A (en) | 2001-03-22 |
Family
ID=42041222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003616 ECSP003616A (en) | 2000-08-11 | 2000-08-11 | MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003616A (en) |
-
2000
- 2000-08-11 EC ECSP003616 patent/ECSP003616A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU94046316A (en) | Use of high effective phosphonates for preparing medicinal agents for osteoporosis treatment | |
| BR9306841A (en) | Pharmaceutical composition process for providing an antihistamine treatment which does not induce any significant cardiac arrhythmia in a human patient and use of a composition for the manufacture of a medicine for use in an antihistamine treatment | |
| ES2187575T3 (en) | CYCLE HEXAPEPTIDES GIVEN WITH ANTIBIOTIC ACTIVITY. | |
| ES2062392T3 (en) | MEDICATIONS INCLUDING SALMETEROL AND FLUTICASONE. | |
| BRPI0015284B8 (en) | controlled release hydrocodone formulations | |
| HUP0100437A2 (en) | Therapeutic formulation for administering tolterodine with controlled release | |
| ATE113203T1 (en) | PHARMACEUTICAL FORM FOR ADMINISTRATION OF AN ANTIPARKINSONIC AGENT. | |
| BR9916860A (en) | Method of reducing blood cholesterol and / or other blood glycerides in a mammal individual, preparation in the form of a dosage unit, and, set to orally administer the same | |
| GB2285219A (en) | Use of norastemizole for the treatment of allergic disorders | |
| KR950007848A (en) | Treatment of Anxiety with (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| DK0629400T3 (en) | Idebenone-containing preparations for the treatment of Alzheimer's disease | |
| JP2003514025A5 (en) | ||
| AR025549A1 (en) | MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA | |
| ES2115571T3 (en) | USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES. | |
| ECSP003616A (en) | MOFETIL MYCOPHENOLATE IN ASSOCIATION WITH PEG-IFN-ALFA | |
| NO971899L (en) | Use of £ R- (Z) | - <alfa> - (methoxyimino) - <alfa> - (1 azabicyclo £ 2.2.2 | oct-3-yl) acetonitrile to reduce amyloid <beta> -A4 formation in Alzheimer's disease | |
| DE69531166D1 (en) | MEDICINAL PRODUCT TO RELEASE THE SIDE EFFECTS CAUSED BY IMMUNE SUPPRESSIVES | |
| RU2002129298A (en) | APPLICATION OF GALANTAMINE FOR THE TREATMENT OF PSYCHONEUROLOGICAL BEHAVIOR ASSOCIATED WITH ALZHEIMER'S DISEASE | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| UY26292A1 (en) | MYCOPHENOLATE MOFETILE IN ASSOCIATION WITH PEG-IFN-A LAW 17164 | |
| YU9302A (en) | Mycophenolate mofetil in association with peg-ifn-alpha | |
| BR0009327A (en) | Pharmaceutical composition for therapy of lower urinary tract symptoms | |
| MX9303074A (en) | USE OF (E) -2- (P-FLUOROFENETIL) -3-FLUOROALILAMINA IN THE TREATMENT OF ELZHEIMER'S DISEASE. | |
| BR0114339A (en) | Pharmaceutically acceptable compositions containing epinastine and pseudoephedrine |